BACKGROUND: The present study determined if, akin to cocaine, nicotine self-administration in rats induces adaptations in the expression of glutamate transporters and cystine-glutamate exchangers in brain nuclei implicated in reinforcement and if treating cigarette smokers with a drug that restores cystine-glutamate exchange affects the number of cigarettes smoked. METHODS: Rats self-administered nicotine intravenously for 12 hours/day or received nicotine through osmotic minipumps for 21 days. Somatic signs of withdrawal were measured and immunoblotting was performed 12 hours after the last nicotine exposure to determine if the catalytic subunit of the cystine-glutamate exchanger, xCT, or the glial glutamate transporter, GLT-1, were altered in the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, or amygdala. For the smoking reduction study in humans, nicotine-dependent smokers were treated for 4 weeks with N-acetylcysteine (2400 mg daily) to promote cystine-glutamate exchange or placebo. Participants provided weekly ratings of withdrawal symptoms, craving, and carbon monoxide (CO) measurements and logged daily cigarette and alcohol use. RESULTS: Rats receiving nicotine via self-administration or minipumps displayed somatic signs of withdrawal, but only nicotine self-administering rats showed decreased xCT expression in the nucleus accumbens and VTA and decreased GLT-1 expression in the nucleus accumbens. Human smokers treated with N-acetylcysteine reported a reduction in cigarettes smoked, and there was no effect of N-acetylcysteine on estimates of CO levels, craving, or withdrawal. CONCLUSIONS: These results indicate that the cystine-glutamate exchanger and the glial glutamate transporter are downregulated after nicotine self-administration, and augmenting exchanger activity with N-acetylcysteine reduced the number of cigarettes smoked in nicotine-dependent individuals.
RCT Entities:
BACKGROUND: The present study determined if, akin to cocaine, nicotine self-administration in rats induces adaptations in the expression of glutamate transporters and cystine-glutamate exchangers in brain nuclei implicated in reinforcement and if treating cigarette smokers with a drug that restores cystine-glutamate exchange affects the number of cigarettes smoked. METHODS:Rats self-administered nicotine intravenously for 12 hours/day or received nicotine through osmotic minipumps for 21 days. Somatic signs of withdrawal were measured and immunoblotting was performed 12 hours after the last nicotine exposure to determine if the catalytic subunit of the cystine-glutamate exchanger, xCT, or the glial glutamate transporter, GLT-1, were altered in the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, or amygdala. For the smoking reduction study in humans, nicotine-dependent smokers were treated for 4 weeks with N-acetylcysteine (2400 mg daily) to promote cystine-glutamate exchange or placebo. Participants provided weekly ratings of withdrawal symptoms, craving, and carbon monoxide (CO) measurements and logged daily cigarette and alcohol use. RESULTS:Rats receiving nicotine via self-administration or minipumps displayed somatic signs of withdrawal, but only nicotine self-administering rats showed decreased xCT expression in the nucleus accumbens and VTA and decreased GLT-1 expression in the nucleus accumbens. Human smokers treated with N-acetylcysteine reported a reduction in cigarettes smoked, and there was no effect of N-acetylcysteine on estimates of CO levels, craving, or withdrawal. CONCLUSIONS: These results indicate that the cystine-glutamate exchanger and the glial glutamate transporter are downregulated after nicotine self-administration, and augmenting exchanger activity with N-acetylcysteine reduced the number of cigarettes smoked in nicotine-dependent individuals.
Authors: Aric Madayag; Doug Lobner; Kristen S Kau; John R Mantsch; Omer Abdulhameed; Matthew Hearing; Mark D Grier; David A Baker Journal: J Neurosci Date: 2007-12-19 Impact factor: 6.167
Authors: Paul J Kenny; Elena Chartoff; Marisa Roberto; William A Carlezon; Athina Markou Journal: Neuropsychopharmacology Date: 2008-04-16 Impact factor: 7.853
Authors: Steven D LaRowe; Hugh Myrick; Sarra Hedden; Pascale Mardikian; Michael Saladin; Aimee McRae; Kathleen Brady; Peter W Kalivas; Robert Malcolm Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher Journal: Antioxid Redox Signal Date: 2012-08-03 Impact factor: 8.401
Authors: Jonna M Leyrer-Jackson; Jose A Piña; Joseph McCallum; M Foster Olive; Cassandra D Gipson Journal: Brain Struct Funct Date: 2020-06-26 Impact factor: 3.270
Authors: Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee Journal: Sci Transl Med Date: 2011-09-28 Impact factor: 17.956
Authors: Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure; Rachel L Tomko; Vitria Adisetiyo; Kevin M Gray Journal: Addict Behav Date: 2016-08-04 Impact factor: 3.913